erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
researchers examined 1,714 samples over six months and found that just 39 per cent contained what they buyer thought they had been sold
.